2017
DOI: 10.1158/1078-0432.ccr-17-0299
|View full text |Cite
|
Sign up to set email alerts
|

Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay

Abstract: Purpose-Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine tumor of the skin. Merkel cell polyomavirus (MCPyV) plays an oncogenic role in the majority of MCCs. Detection of MCPyV in MCCs has diagnostic utility and prognostic potential. We investigated whether RNAscope, an RNA in situ hybridization (ISH) assay for detection of RNA transcripts in tissues, is useful for MCPyV detection.Experimental Design-We applied an RNAscope probe targeting MCPyV T antigen transcripts on tissue microarrays (TMAs… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
32
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 35 publications
(35 citation statements)
references
References 38 publications
3
32
0
Order By: Relevance
“…Currently, the methods used for the experimental detection or diagnosis of MCV in tumours include immunohistochemistry, PCR, RNA or DNA in situ hybridization and next-generation sequencing (NGS) 3,12,[33][34][35][36][37] . All of these assays vary considerably in terms of sensitivity and specificity for MCV detection in tumours.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, the methods used for the experimental detection or diagnosis of MCV in tumours include immunohistochemistry, PCR, RNA or DNA in situ hybridization and next-generation sequencing (NGS) 3,12,[33][34][35][36][37] . All of these assays vary considerably in terms of sensitivity and specificity for MCV detection in tumours.…”
Section: Discussionmentioning
confidence: 99%
“…Technical factors, including inefficient PCR amplification owing to mutations in the integrated MCPyV genome, primer incompatibilities, low purity of tumour samples or the detection of infectious wild-type MCPyV in the adjacent nonmalignant skin often confound the results for such tests 19,35 . Besides, qPCR does not allow for visual confirmation that positive results are associated with tumour cells; hence, background MCV presence cannot be excluded in MCC tumours with low signal 35 .…”
Section: Discussionmentioning
confidence: 99%
“…no. 322350; Advanced Cell Diagnostics, Newark, CA, USA) was performed using target probes to MCPyV on tissue sections according to the manufacturer's instructions and methods followed by Wang et al 24 Human peptidylprolyl isomerase B (Hs-PPIB) and bacterial dihydrodipicolinate reductase (DapB) were used as positive and negative controls, respectively. FFPE HeLa cells (Advanced Cell Diagnostics) were also used as negative and positive controls, as suggested by Advanced Cell Diagnostics.…”
Section: Rna-in Situ Hybridizationmentioning
confidence: 99%
“…1 MCPyV, present in 60% to 80% of MCC tumors, may be detected by immunohistochemistry, RNA in situ hybridization, or polymerase chain reaction (PCR). 1,2,23 MCCIS displays similar patterns of diagnostic marker expression, although staining may be more focal, and cytoplasmic cytokeratin staining may be more frequent. 22 MCPyV has been reported in association with one case of MCCIS; other cases have been negative for MCPyV, or were not tested.…”
Section: Introductionmentioning
confidence: 99%
“…Of note, MCC may express certain lymphoid markers such as TdT or PAX5; however, CD45, CD3, and CD20 are reliably negative . MCPyV, present in 60% to 80% of MCC tumors, may be detected by immunohistochemistry, RNA in situ hybridization, or polymerase chain reaction (PCR) . MCCIS displays similar patterns of diagnostic marker expression, although staining may be more focal, and cytoplasmic cytokeratin staining may be more frequent .…”
Section: Introductionmentioning
confidence: 99%